MAPK3 and Familial prostate cancer: Treatment with LHR-siRNA can prevent LH-mediated proliferation and androgen synthesis of prostate cancer cells, and downregulate the expressions of AR, PSA, PKA, ERK1/2, PI3K, AKT2 and HER2 (Xiong et al., 2015).